Program (per 2025-08-29)

2025-09-10

Educational Day – See separate site here.

2025-09-11

• 08:00 – 08:45 | Registration
• 08:45 – 09:00 | Welcome and Opening: Bjørn Tore Gjertsen (Chair, Nordic AML Group)
• Session 1 | Novel therapies in AML
  • Chairs: Marianne Tang Severinsen, Pia Ettala
  • 09:00 – 09:30 | Hartmut Döhner: NAMLG Keynote Lecture: Genetics guiding therapy: Ongoing clinical trials and new initiatives
  • 09:30 – 10:00 | Gerwin Huls: Menin inhibition in AML treatment
• 10:00 – 10:45 | Coffee break
• Session 2 | Genomics in AML – from bench to bedside
  • Chairs: Anne Stidsholt Roug, Sören Lehmann
  • 10:45 – 11:20 | Konstanze Döhner: SKGJ CMYC Keynote Lecture: Molecular Genetics of Myeloid Leukemia
  • 11:20 – 11:40 | Anna Staffas: Whole genome and transcriptome sequencing for AML diagnostics in Sweden
  • 11:40 – 12:00 | Anne Stridsholt Roug: Precision Medicine Diagnostics of AML in Denmark
• 12:00 – 13:15 | Lunch break
• Session 3 | Specialized parallel sessions
• Session 3A | Epigenetics / TP53 mutations
  • Chairs: Kim Theilgaard-Mönch, Mika Kontro
  • 13:15 – 13:45 | Kirsten Grønbæk, KG Jebsen Centre Keynote Lecture: Targeting epigenetics in myeloid malignancy and precursor conditions – an opportunity for interception?
  • 13:45 – 14:05 | Sören Lehmann: Chromatin organization in AML
  • 14:05 – 14:35 | Klas G Wiman, Dentist Olaf Aase and wife memorial lecture: Targeting mutant p53 in hematological malignancies
  • 14:35 – 14:50 | Amos Tuval: p53 conformation as a non-genomic marker for p53-dysfunction in AML
•  Session 3B | | Analysis of measurable residual disease (MRD)
  • Chairs: Anna Staffas, Rakel Forthun (Diagnostic working group)
  • 13:15 – 13:40 | Hans B Ommen: Molecular MRD targeting AML-specific mutations in non-NPM1 AML
  • 13:40 – 14:05 | Sofie J Alm: Next generation sequencing-MRD for FLT3-ITD and rare NPM1 variants
  • 14:05 – 14:30 | Lucia Cavelier Franco: Towards higher sensitivity in molecular MRD
  • 14:30 – 14:50 | Signe Modvig: Cross-platform and -country harmonization of flow cytometry MRD in pediatric AML

• 14:50 – 15:30 | Coffee break

• Session 4 | Immunology/Epigenetics/Immunotherapy including CAR T 
  • Chairs: Bjørn Tore Gjertsen, Martin Jädersten
  • 15:30 – 16:10 | Satu Mustjoki: NAMLG Keynote Lecture: Immunoregulation in myeloid blood cancer
  • 16:10 – 16:30 | Helena Ågerstam: Target Identification on AML Stem Cells: From Bench to Clinical Trials
  • 16:30 – 16:50 | Kristoffer Hellstrand: Immunotherapy for relapse prevention in normal karyotype AML
• 17:00 – 18:30 | Poster-walk and presentations + exhibition + snacks + wine etc.
• 19:15 – 22:30 | Conference Dinner at Akvariet Restaurant

2025-09-12

• Session 5: Clinical hematology
  • Chairs: Albin Österroos, Daniel Tuyet Kristensen
  • 08:45 – 09:30 | Christoph Röllig, NAMLG Keynote Lecture: The changing landscape of AML induction
  • 09:30 – 10:00 | Martin Jädersten:  The HEAT-AML trial: Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed AML
• 10:00 – 10:05 | Announcement of Acta Oncologica Poster Prize
• 10:05 – 10:45 | Coffee break
• Session 6: How I treat relapsed / refractory (RR) AML
  • Chairs: Pia Ettala, Christer Nilsson
  • 10:45 – 11:05 | Markus Liew-Littorin: Real-world outcomes for primary refractory AML (20 min)
  • 11:05 – 11:25 | Mika Kontro: How I treat RR AML in Helsinki
  • 11:25 – 11:45 | Martin Jädersten: How I treat RR AML in Stockholm
  • 11:45 – 12:05 | Bjørn Tore Gjertsen: How I treat RR AML in Bergen
  • 12:05 – 12:30 | Panel discussion

• 12:30 – 13:30 | Lunch break
• Session 7: From emerging target to standard-of-care in AML
  • Chair: Anne Louise Tølbøll Sørensen, Mika Kontro
  • 13:30 – 13:50 | Kim Theilgaard-Mønch: Targeting oncofetal chondroitin sulfate in AML
  • 13:50 – 14:30 | Anne Louise Tølbøll Sørensen: Azacitidine in combination with reduced duration venetoclax in patients with de novo, secondary, and relapsed/refractory AML
  • 14:30 – 15:00 | Olli Kallioniemi: Data and AI-driven strategies for precision medicine in AML
• 15:00 – 15:15 | Closing remarks